// App-Quantinova.ai

1427 : A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

Researchers

Presenter

  • Hetty E Carraway

Principal Investigators

  • Judith E. Karp

  • Ivana Gojo

  • Lia Gore

  • Min-Jung Lee

  • Sunmin Lee

  • Peter Ordentlich

  • Richard Piekarz

  • Jane Trepel

  • Keith W. Pratz

  • Nilanjan Ghosh

  • Steven D. Gore

  • Margaret M. Showel

  • Mark Levis

  • B. Douglas Smith

  • Jacqueline Greer

  • James G. Herman

Medical Centers

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Cancer Biology Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • Syndax Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Peripheral T-cell lymphoma

  • T-cell lymphoma

  • Bacterial Skin Infection

  • Lymphomas

  • Solid malignancies

  • Cutaneous T-cell lymphoma

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Alanine transaminase

  • Aspartate aminotransferase

  • Breakpoint Cluster Region

  • Ph chromosome

  • Creatinine

  • White Blood Cell

  • DNA methylation

Drug/Treatment

  • Cytarabine liposomal

  • Clofarabine

  • fludarabine tablet

  • Entinostat

  • ara-c

Outcome

  • N/A

Study Design

  • fixed dose

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved